-
A spokesperson for CVS Health said that the company would exclusively cover new migraine drugs from Eli Lilly and Teva, as reported NASDAQ Friday.
-
CVS spokeswoman Christine Cramer indicated that Teva's Ajovy and Eli Lilly's Emgality will be available for members who failed to respond to other preventative migraine treatments.
-
Under the decision, the pharmacy benefits manager will exclude Amgen's Aimovig from coverage.
-
An Amgen spokeswoman expressed that the drugmaker was disappointed by the move, adding that it planned to work to ensure that Aimovig is considered a preferred brand on CVS coverage lists.
-
Shares in Amgen were down 1.3 percent on the news, while shares in Teva jumped by the same percentage.










(All Rights Reserved)